OXiGENE To Present at UBS Global Life Sciences Conference in NYC September 27

OXiGENE To Present at UBS Global Life Sciences Conference in NYC September 27

Presentation  Available via Webcast

    WALTHAM, Mass.--(BUSINESS WIRE)--Sept. 19, 2007--Regulatory News:

    OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a clinical stage,
biopharmaceutical company developing novel therapeutics to treat
cancer and eye diseases, announced today that the company will present
at the UBS Global Life Sciences Conference at The Grand Hyatt Hotel in
New York, New York on Thursday, September 27, 2007 at 4:00 pm EDT.

    A live and archived webcast of the presentation can be accessed at
www.oxigene.com.

    About OXiGENE, Inc.

    OXiGENE is a clinical-stage biotechnology company developing novel
small-molecule therapeutics to treat cancer and eye diseases. The
Company's major focus is the clinical advancement of drug candidates
that selectively disrupt abnormal blood vessels associated with solid
tumor progression and visual impairment. OXiGENE is dedicated to
leveraging its intellectual property position and therapeutic
development expertise to bring life saving and enhancing medicines to
patients.


CONTACT: OXiGENE, Inc.
         Shari Annes, 650-888-0902
         Investor Relations
         sannes@oxigene.com